ca209-9ky: imrt nivolumab for recurrent head and neck squamous cell cancer
Published 2 years ago • 365 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:40
matisse: nivolumab in cutaneous squamous cell carcinoma
-
1:09
the future role of immunotherapy in head and neck cancers
-
1:52
esmo 2022 highlights in head and neck cancer
-
2:12
unanswered questions in head and neck cancer
-
6:51
pembrolizumab and nivolumab in recurrent hnscc
-
1:21
key areas of unmet need in head and neck squamous cell carcinoma
-
1:13
radiation and adjuvant nivolumab in hpv oropharynx cancer
-
3:34
irec: international center for recurrent head and neck cancer
-
3:04
head and neck cancer at asco 2022
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
4:06
immunotherapy for head and neck cancer treatment
-
1:23
squint: nivolumab ipilimumabi v platinum-based ct nivolumab in advanced lung squamous cell carcinoma
-
3:14
factors predicting the outcome of immunotherapy to patients with head and neck cancer
-
7:13
nivolumab confers better os in patients with metastatic squamous cell carcinoma of the head and neck
-
1:41
phase ii trial of pembrolizumab and cabozantinib in hnscc
-
1:15
dr. ferris on significance of checkmate-141 trial for head and neck cancer
-
1:17
dr. ferris on fda approval of nivolumab in patients with head and neck cancer
-
3:05
asco 2020: head and neck cancer highlights